In this episode, Anthony and Bernie are joined once again by special guest and hematology expert, Dr. Dale Bixby, to discuss the recent publication of the QUANTUM-First study of quizartinib in newly diagnosed AML. Should this study change practice in FLT3-ITD+ AML? Have we made a "Quantum Leap" in the treatment of these patients? Listen for a fun-filled discussion of the data!
Notable References:
- QUANTUM-First Study: https://pubmed.ncbi.nlm.nih.gov/37116523/
- WolverHeme Episode 8 (Pulling the Goalie on FLT3 Inhibitor Use in AML): https://podcasters.spotify.com/pod/show/wolverheme/episodes/Episode-8-Pulling-the-Goalie-on-FLT3-Inhibitor-Use-in-AML---A-Discussion-with-Dr--Dale-Bixby-e1r6tqt/a-a8tthkc
WolverHeme Happy Hour